Nitsan Halevy
Director Técnico/Científico/I+D en PLURI INC. .
Perfil
Nitsan Halevy is currently the Chief Medical Officer at Pluri, Inc. Prior to this, she worked as the Chief Development Officer at Quark Pharmaceuticals, Inc. She holds a doctorate degree from Ben-Gurion University of the Negev.
Cargos activos de Nitsan Halevy
| Empresas | Cargo | Inicio |
|---|---|---|
| PLURI INC. | Director Técnico/Científico/I+D | 01/03/2021 |
Antiguos cargos conocidos de Nitsan Halevy.
| Empresas | Cargo | Fin |
|---|---|---|
Quark Pharmaceuticals, Inc.
 Quark Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Quark Pharmaceuticals, Inc. discovers and develops novel RNAi-based therapeutics. The firm’s products include QPI-1002 and QPI-1007 is being developed as a neuroprotective agent for the treatment of optic neuropathies that result in the death of retinal ganglion cells. The company was founded by Daniel Zurr, David M. Fineman and J. Gregory Swendsen in December 1993 and is headquartered in Fremont, CA. | Corporate Officer/Principal | - |
Formación de Nitsan Halevy.
| Ben-Gurion University of the Negev | Doctorate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 1 |
|---|---|
| PLURI INC. | Health Technology |
| Empresas privadas | 1 |
|---|---|
Quark Pharmaceuticals, Inc.
Quark Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Quark Pharmaceuticals, Inc. discovers and develops novel RNAi-based therapeutics. The firm’s products include QPI-1002 and QPI-1007 is being developed as a neuroprotective agent for the treatment of optic neuropathies that result in the death of retinal ganglion cells. The company was founded by Daniel Zurr, David M. Fineman and J. Gregory Swendsen in December 1993 and is headquartered in Fremont, CA. | Health Technology |
- Bolsa de valores
- Insiders
- Nitsan Halevy
